Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study

BACKGROUND AND AIM: Alzheimer disease (AD) is the most common cause of dementia. Currently, there is no disease-modifying therapy for AD. We aimed to evaluate the long-term efficacy and safety of MLC601 in the treatment of AD. METHODS: In this open-label extension study, patients with mild to modera...

Descripción completa

Detalles Bibliográficos
Autores principales: Pakdaman, Hossein, Gharagozli, Koroush, Abbasi, Mehdi, Sobhanian, Ali, Bakhshandehpour, Ali, Ashrafi, Farzad, Khalilzad, Mitra, Amini Harandi, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968230/
https://www.ncbi.nlm.nih.gov/pubmed/29805383
http://dx.doi.org/10.1159/000488482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968230/
https://www.ncbi.nlm.nih.gov/pubmed/29805383
http://dx.doi.org/10.1159/000488482

Ejemplares similares